Novavax Inc. (NVAX) Announces Results for Seasonal Influenza Vaccine Candidate
Novavax Inc. (Nasdaq: NVAX) today announced positive results from its immunogenicity study in ferrets inoculated with the company’s seasonal influenza vaccine candidate. The results allow Novavax to complete its new investigational drug application in support of Phase II clinical trials in the third quarter of this year. "Novavax' influenza programs are moving forward rapidly as planned," Dr. Penny Heaton, Novavax' Chief Medical Officer and vice president of Development stated in the press release. "In addition to the positive results from our seasonal influenza vaccine candidate announced today, the dose-ranging study of our H5N1 pandemic flu vaccine is enrolling as projected…